ATNM_OUT_1 [2025-04-29 11:41:24 -0400] 8077 Bytes | 2122 tokens | Cum: 2122 tkns (26.52% of 8k)
==========================================================================

Captain's log, 11:41 AM on Tue Apr 29, 2025. Target in sight: Actinium Pharmaceuticals (ATNM), moving from $1.30 to $1.47. Risk: acceptable. Opportunity: unknown. We proceed to analysis.

--- COMPANY PROFILE ---
Company: Actinium Pharmaceuticals (ATNM)
IPO: 2007-07-19 (17 Years Ago)
Market Cap: $46,481,878
Shares Outstanding: 31,200,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XASE
Description: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Here’s a list of headlines for Actinium Pharmaceuticals:

Apr-28-25 08:30AM - Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
Apr-28-25 08:30AM 08:00AM - Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
Apr-18-25 12:50PM - Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights ATNM
Apr-14-25 10:15AM - With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
Apr-10-25 12:24PM - Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights ATNM
Apr-08-25 05:45AM - Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Apr-07-25 01:40PM - Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights ATNM
Apr-04-25 05:45AM - Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Mar-27-25 08:45AM - Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Mar-27-25 08:45AM 07:30AM - Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
Mar-26-25 08:45AM - Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
Mar-25-25 06:00AM - Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
Mar-24-25 04:15PM - Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
Mar-20-25 08:00AM - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
Mar-19-25 08:30AM - Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
Mar-19-25 08:30AM 08:11AM - Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
Mar-18-25 08:00AM - Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO
Mar-17-25 08:50AM - Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Mar-12-25 08:00AM - Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Mar-11-25 08:30AM - Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Nov-18-24 08:00AM - Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
Nov-14-24 07:02PM - Actinium: Q3 Earnings Snapshot

Prior AI Reports for ATNM:
1. 2025-03-26 – Score: 51 – Target: 2.3700 – Highs: 2.4100 / 2.0100 / 1.98
mixed-signals-company-sees-volume-surge-but-lacks-revenue
2. 2025-03-25 – Score: 85 – Target: 2.3800 – Highs: 2.2399 / 2.4100 / 2.01
actinium-pharmaceuticals-volatile-performance-with-potential-upside
3. 2025-03-20 – Score: 60 – Target: 2.2000 – Highs: 1.4900 / 1.5700 / 1.59
short-squeeze-potential-amid-actiniums-financial-woes

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-29T01:00:00Z - Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
B2 - 2025-04-25T20:00:00Z - ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
B3 - 2025-04-22T22:47:00Z - ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
B4 - 2025-04-22T01:00:00Z - Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
B5 - 2025-04-20T12:44:00Z - DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
B6 - 2025-04-18T20:00:00Z - ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Actinium Pharmaceuticals (ATNM).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ATNM_OUT_3 [2025-04-29 11:41:24 -0400] 971 Bytes | 264 tokens | Cum: 2388 tkns (29.85% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/25/3068606/9788/en/ATNM-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Actinium-Pharmaceuticals-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.htmlA class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making materially false and misleading statements about the likelihood of FDA approval for its drug Iomab-B.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_5 [2025-04-29 11:41:25 -0400] 1014 Bytes | 266 tokens | Cum: 2656 tkns (33.20% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T22:28:00Z - ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit...
A2 - 2025-04-28T22:28:00Z - ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit...
A3 - 2025-04-28T22:28:00Z - ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit...
A4 - 2025-04-28T22:28:00Z - ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit...
A5 - 2025-04-28T22:28:00Z - ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ATNM_OUT_7 [2025-04-29 11:41:26 -0400] 1181 Bytes | 328 tokens | Cum: 2986 tkns (37.33% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit**Date: 2025-04-29Source: {'uri': 'keenesentinel.com', 'dataType': 'news', 'title': 'SentinelSource.com'}URL: https://www.keenesentinel.com/online_features/press_releases/atnm-investors-have-opportunity-to-lead-actinium-pharmaceuticals-inc-securities-fraud-lawsuit/article_d02c1df7-7442-5654-a23b-2c993ed2b1f3.htmlNEW YORK, April 28, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 26, 2025 lead plaintiff deadline.

So what: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or cos

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_9 [2025-04-29 11:41:27 -0400] 1181 Bytes | 275 tokens | Cum: 3263 tkns (40.79% of 8k)
==========================================================================

Showing A1 (chunk 2 of 6): ts through a contingency fee arrangement.

What to do next: To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_11 [2025-04-29 11:41:28 -0400] 1181 Bytes | 263 tokens | Cum: 3528 tkns (44.10% of 8k)
==========================================================================

Showing A1 (chunk 3 of 6): ally litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendan

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_13 [2025-04-29 11:41:29 -0400] 1181 Bytes | 282 tokens | Cum: 3812 tkns (47.65% of 8k)
==========================================================================

Showing A1 (chunk 4 of 6): ts made false and/or misleading statements and/or failed to disclose that: (1) Actinium's data from Sierra Trial was unlikely to satisfy the U.S. Food and Drug Administration's ("FDA") guidelines for the acceptance and approval of Actinium's Iomab-B Biologics License Application ("BLA"); (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival ("OS") that Actinium provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Actinium's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about Actinium's business, operations, and prosp

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_15 [2025-04-29 11:41:29 -0400] 1181 Bytes | 281 tokens | Cum: 4095 tkns (51.19% of 8k)
==========================================================================

Showing A1 (chunk 5 of 6): ects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_17 [2025-04-29 11:41:30 -0400] 836 Bytes | 249 tokens | Cum: 4346 tkns (54.33% of 8k)
==========================================================================

Showing A1 (chunk 6 of 6):
Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/atnm-investors-have-opportunity-to-lead-actinium-pharmaceuticals-inc-securities-fraud-lawsuit-302440312.html

SOURCE THE ROSEN LAW FIRM, P. A.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_19 [2025-04-29 11:41:32 -0400] 1054 Bytes | 259 tokens | Cum: 4607 tkns (57.59% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S8 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

The information and financial data discussed below is derived from the audited CONS financial statements of Actinium Pharmaceuticals, Inc. for its fiscal years ended December ...

S9 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S10 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which i...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATNM_OUT_21 [2025-04-29 11:41:33 -0400] 1181 Bytes | 245 tokens | Cum: 4854 tkns (60.68% of 8k)
==========================================================================

Showing S8 (chunk 1 of 6): S8:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The information and financial data discussed below is derived from the audited consolidated financial statements of Actinium Pharmaceuticals, Inc. for its fiscal years ended December 31, 2024 and 2023. The consolidated financial statements of Actinium Pharmaceuticals, Inc. were prepared and presented in accordance with generally accepted accounting principles in the United States. The information and financial data discussed below is only a summary and should be read in conjunction with the historical financial statements and related notes of Actinium Pharmaceuticals, Inc. contained elsewhere in this Report. The financial statements contained elsewhere in this Report fully represent Actinium Pharmaceuticals, Inc.s financial condition and operations; however, they are not indicative of the

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_23 [2025-04-29 11:41:34 -0400] 1181 Bytes | 261 tokens | Cum: 5117 tkns (63.96% of 8k)
==========================================================================

Showing S8 (chunk 2 of 6): Companys future performance. See Cautionary Note Regarding Forward-Looking Statements above for a discussion of forward-looking statements and the significance of such statements in the context of this Report. See also Risk Factors in Part I, Item 1A of this Report for a discussion of risks and uncertainties that could impact Actinium Pharmaceuticals, Inc.s future financial condition, operations and performance.

Actinium Pharmaceuticals, Inc. (Actinium, the Company, or we) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients with relapsed or refractory cancer who have failed existing therapies. We operate as a single operating segment focused on research, discovery, and clinical development of targeted radiotherapies.

Results of Operations Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023

The follow

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_25 [2025-04-29 11:41:35 -0400] 1181 Bytes | 321 tokens | Cum: 5440 tkns (68.00% of 8k)
==========================================================================

Showing S8 (chunk 3 of 6): ing table sets forth, for the periods indicated, data derived from our statements of operations:

##TABLE_START For the years ended December 31, Increase (amounts in thousands) 2024 2023 (Decrease) Revenue: Revenue $ - $ - $ - Other revenue - 81 (81 ) Total revenue - 81 (81 ) Operating expenses: Research and development, net of reimbursements 30,045 38,670 (8,625 ) General and administrative 12,076 13,331 (1,255 ) Total operating expenses 42,121 52,001 (9,880 ) Other income: Interest income net 3,878 3,102 776 Total other income 3,878 3,102 776 Net loss $ (38,243 ) $ (48,818 ) $ (10,575 ) ##TABLE_END

Revenues

We recorded no commercial revenues for the years ended December 31, 2024 and 2023, respectively.

Other revenue

The National Institutes of Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan Ke

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_27 [2025-04-29 11:41:36 -0400] 1181 Bytes | 288 tokens | Cum: 5730 tkns (71.62% of 8k)
==========================================================================

Showing S8 (chunk 4 of 6): ttering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. We recognized other revenue during the year ended December 31, 2023 of $0.1 million from this grant.

On April 7, 2022, we entered into a License Agreement with Immedica, pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable payment of $35.0 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from the License Agreeme

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_29 [2025-04-29 11:41:37 -0400] 1181 Bytes | 261 tokens | Cum: 5993 tkns (74.91% of 8k)
==========================================================================

Showing S8 (chunk 5 of 6): nt. We continue to retain commercialization rights in the U.S. and rest of the world.

Our contract liabilities are recorded within Other revenue deferred current liability or Long-term license revenue deferred in our condensed consolidated balance sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was $35.0 million at December 31, 2024 and December 31, 2023, resulting from the receipt from Immedica; this deferred revenue will be recognized upon the European Unions regulatory approval of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.

Research and Development Expenses, net of reimbursements

Research and development expenses decreased by $8.6 million to $30.0 million for the y

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_31 [2025-04-29 11:41:38 -0400] 790 Bytes | 199 tokens | Cum: 6194 tkns (77.42% of 8k)
==========================================================================

Showing S8 (chunk 6 of 6): ear ended December 31, 2024, compared to $38.7 million for the year ended December 31, 2023. This decrease was primarily due to CMC expenses declining by $12.0 million and consulting expenses declining by $1.7 million due to lower CMC activity related to Iomab-B. These declines were partially offset by increased preclinical expenses of $5.0 million.

In the third quarter of 2024, our overall headcount was reduced by approximately twenty percent, with a majority of these former employees being from o...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ATNM_OUT_33 [2025-04-29 11:41:44 -0400] 9329 Bytes | 2654 tokens | Cum: 8850 tkns (110.62% of 8k)
==========================================================================

This is our set of metrics for Actinium Pharmaceuticals.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+-------------------------+
| Volume: 265,788 | Perf Month: -20.17% | Option/Short: Yes / Yes | Sales Y/Y TTM: -100.00% |
+---------------------+----------------------+-------------------------+-------------------------+
| Avg Volume: 617.33K | Perf Quarter: 12.02% | Short Float: 5.50% | ROE: -110.63% |
+---------------------+----------------------+-------------------------+-------------------------+
| Rel Volume: 1.29 | Index: RUT | Short Ratio: 2.71 | ROI: -113.31% |
+---------------------+----------------------+-------------------------+-------------------------+
| RSI (14): 56.53 | Market Cap: 45.07M | Short Interest: 1.67M | Sales Surprise: - |
+---------------------+----------------------+-------------------------+-------------------------+
| ATR (14): 0.16 | Shs Outstand: 31.20M | Beta: -0.20 | EPS Surprise: 30.48% |
+---------------------+----------------------+-------------------------+-------------------------+
| SMA20: 10.83% | Shs Float: 30.40M | Sales Q/Q: -100.00% | P/E: - |
+---------------------+----------------------+-------------------------+-------------------------+
| SMA50: 11.27% | Inst Own: 28.66% | Sales past 5Y: -42.00% | Earnings: Mar 14 |
+---------------------+----------------------+-------------------------+-------------------------+
| SMA200: -27.27% | Insider Own: 2.54% | Employees: 37 | |
+---------------------+----------------------+-------------------------+-------------------------+
| Perf Week: 4.71% | Insider Trans: 0.00% | Debt/Eq: 0.05 | |
+---------------------+----------------------+-------------------------+-------------------------+

The next section covers any insider trading by Actinium Pharmaceuticals officers or majority shareholders (if available).

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by Chell Jeffrey W. (Unknown Title) on 2025-03-31
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 18351 shares at $0 (D)
- Stock Option (Right to Buy): 72156 shares at $0 (D)
- Stock Option (Right to Buy): 70311 shares at $0 (D)

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by Almenoff June Sherie (Unknown Title) on 2025-03-31
- Stock Option (Right to Buy): 50000 shares at $0 (D)

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by Shetty Ajit (Unknown Title) on 2025-03-31
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- tock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 18351 shares at $0 (D)
- Stock Option (Right to Buy): 72156 shares at $0 (D)
- Stock Option (Right to Buy): 70311 shares at $0 (D)

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by Steinhart Richard I (Unknown Title) on 2025-03-31
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 18351 shares at $0 (D)
- Stock Option (Right to Buy): 72156 shares at $0 (D)
- Stock Option (Right to Buy): 70311 shares at $0 (D)

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by O'Loughlin Steve (Chief Financial Officer) on 2025-03-31
- Stock Option (Right to Buy): 3333 shares at $0 (D)
- Stock Option (Right to Buy): 1666 shares at $0 (D)
- Stock Option (Right to Buy): 3333 shares at $0 (D)
- Stock Option (Right to Buy): 8833 shares at $0 (D)
- Stock Option (Right to Buy): 13333 shares at $0 (D)
- Stock Option (Right to Buy): 59066 shares at $0 (D)
- Stock Option (Right to Buy): 107463 shares at $0 (D)
- Stock Option (Right to Buy): 256438 shares at $0 (D)
- Stock Option (Right to Buy): 253123 shares at $0 (D)

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by SETH SANDESH (Chief Executive Officer) on 2025-03-31
- Stock Option (Right to Buy): 16666 shares at $0 (D)
- Stock Option (Right to Buy): 25000 shares at $0 (D)
- Stock Option (Right to Buy): 33333 shares at $0 (D)
- Stock Option (Right to Buy): 50000 shares at $0 (D)
- Stock Option (Right to Buy): 139062 shares at $0 (D)
- Stock Option (Right to Buy): 310182 shares at $0 (D)
- Stock Option (Right to Buy): 827366 shares at $0 (D)
- Stock Option (Right to Buy): 984367 shares at $0 (D)

Inside Trans: Actinium Pharmaceuticals, Inc. (ATNM) by Nicholson, C. David (Unknown Title) on 2025-03-31
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 8333 shares at $0 (D)
- Stock Option (Right to Buy): 18351 shares at $0 (D)
- Stock Option (Right to Buy): 72156 shares at $0 (D)
- Stock Option (Right to Buy): 70311 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -11568000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.465
Average Volume: 385117.14
30-Day High: 1.61
30-Day Low: 1.15

[Detailed Financials: Q3 2024]
- Total Assets: $82,114,000.00
- Total Liabilities: $43,906,000.00
- Total Equity: $38,208,000.00
- Current Assets: $79,520,000.00
- Current Liabilities: $7,755,000.00

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: $-11,568,000.00
- Gross Profit: N/A
- Operating Income: $-12,601,000.00
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-7,373,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $89,861,000.00
- Total Liabilities: $46,026,000.00
- Total Equity: $43,835,000.00
- Current Assets: $87,068,000.00
- Current Liabilities: $9,728,000.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-11,353,000.00
- Gross Profit: N/A
- Operating Income: $-12,418,000.00
- Earnings Per Share (EPS): -0.38

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $1,982,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Actinium Pharmaceuticals (ATNM).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Actinium Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because ATNM is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ATNM.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ATNM could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ATNM to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Actinium Pharmaceuticals.

11) ETHICAL_RATING[]
Rate Actinium Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Actinium Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ATNM_IN_35 [2025-04-29 11:41:45 -0400] 126 Bytes | 29 tokens | Cum: 9090 tkns (113.62% of 8k)
==========================================================================

====================================
[2025-04-29 11:41:45] # Analysis Completed
Elapsed Time: 21.56 seconds